Alnylam Pharmaceuticals

Alnylam UK is the European operational headquarters of Alnylam Pharmaceuticals, the pioneer of RNA interference therapeutics.

Based in Maidenhead, the UK office serves as Alnylam's primary base for European commercial operations, medical affairs, and regulatory activities.

Alnylam has six approved RNAi medicines on the market, with a pipeline spanning rare genetic, cardiometabolic, and CNS diseases.

The company's GalNAc conjugate delivery platform underpins its portfolio of siRNA therapeutics that silence disease-causing genes in the liver.